TransMedics Q3 Revenue Jumps 41% to $203M, Full-Year Guidance Raised to $764-$774M
TMDX sits 28% above its 52-week low of $60.105 on elevated volume (1.8× avg).
Summary
TransMedics posted record Q3 revenue of $203.0 million, up 41%, with net income of $17.1 million, and raised full-year 2026 revenue guidance to $764-$774 million. Diluted EPS still fell to $0.46 from $0.66 as trial and expansion spending rose.
Key Events · Earnings and Guidance · TMDX
-
Record Q3 Revenue of $203M
Total revenue rose 41% to $203.0 million from $143.8 million, with organic growth of 35% after excluding $9.4 million of PAD Aviation charter revenue.
-
Net Income Back to $17.1M
Net income was $17.1 million, or $0.46 per diluted share, versus $24.3 million, or $0.66, a year ago; operating expenses rose to $90.5 million from $61.3 million on OCS Kidney, next-generation OCS and ENHANCE spending.
-
Full-Year Guidance Raised
FY2026 revenue guidance lifted to $764-$774 million including about $14 million from PAD Aviation, from prior guidance of $737-$757 million excluding PAD, implying 26%-28% annual growth.
-
Two New FDA IDE Approvals
In October the FDA approved IDE for ENHANCE Heart Part B and DENOVO Lung, and a continued access protocol allowing enrollment of 90 additional patients.
Analysis · TMDX · Industrial Applications And Services
The headline for a growth medtech still proving its margin story is the guidance raise, and TransMedics delivered it alongside its strongest quarter on record. Revenue of $203.0 million rose 41% (35% organic, excluding the newly acquired PAD Aviation), and net income swung back to $17.1 million after Q2's 58% profit decline. Profitability per share is the catch: diluted EPS fell to $0.46 from $0.66 a year ago as operating expenses climbed to $90.5 million on OCS Kidney, next-generation OCS and ENHANCE trial spending. Guidance now sits at $764-$774 million including roughly $14 million from PAD Aviation, up from $737-$757 million excluding it. Beyond the current liver and heart business, the growth runway extends through two new FDA IDE approvals (ENHANCE Heart Part B and DENOVO Lung) and a first European logistics tender in Italy.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TMDX was trading at $76.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $60.11 to $156.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.